-+ 0.00%
-+ 0.00%
-+ 0.00%

Abera Bioscience nasal pneumococcal vaccine Ab-01.12 advances toward Phase 1 trial in Netherlands

PUBT·10/14/2026 09:01:01
Abera Bioscience nasal pneumococcal vaccine Ab-01.12 advances toward Phase 1 trial in Netherlands
  • Abera Bioscience AB reported a new npj Vaccines paper summarizing preclinical work supporting its intranasal pneumococcal vaccine candidate Ab-01.12.
  • Results were already presented in the publication; human safety and immune response data will be generated in a planned Phase 1 trial.
  • Animal studies showed the candidate was tolerated, triggered immune responses, reduced nasal colonization, and supported durability of protection.
  • Preparations for Phase 1 remain on track; the Clinical Trial Application is under review by Dutch authorities.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abera Bioscience AB published the original content used to generate this news brief via Cision (Ref. ID: 202610140459BITN____UKPR__SV_20261014-BIT-3245-0) on October 14, 2026, and is solely responsible for the information contained therein.